Pirtobrutinib (3) – Jaypirca®
Chronic lymphocytic leukaemia (CLL), monotherapy
Characteristics
| Start date | 01.09.2026 |
|---|---|
| Resolution | 18.02.2027 – active procedure |
| INN | Pirtobrutinib |
| Brand name | Jaypirca® |
| Pharm. company | Lilly Deutschland GmbH |
| G-BA Procedure ID | D-1373 |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Pirtobrutinib (3) | Jaypirca® | Lilly Deutschland GmbH | Chronic lymphocytic leukaemia (CLL), monotherapy | n.d. | active procedure | |
| Pirtobrutinib (2) | Jaypirca® | Lilly Deutschland GmbH | Chronic lymphocytic leukaemia (CLL), relapsed or refractory, monotherapy | 5,390–7,490 | 9% Hint for minor additional benefit | |
| Pirtobrutinib (1) | Jaypirca® | Lilly Deutschland GmbH | Mantle cell lymphoma, pre-treated patients | 105–150 | 100% additional benefit not proven |
<< List of all resolutions